{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:26:16Z","timestamp":1795112776567,"version":"4.10.3"},"reference-count":52,"publisher":"Informa UK Limited","issue":"30","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK plc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2024,9,22]]},"DOI":"10.1080\/14796694.2024.2368450","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T10:53:35Z","timestamp":1722250415000},"page":"2259-2270","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6624-4196","authenticated-orcid":false,"given":"Lucia","family":"Masarova","sequence":"first","affiliation":[{"name":"Department of Leukemia,\u00a0Division of Cancer Medicine,\u00a0The University of Texas MD Anderson Cancer, Houston, TX 77030,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"Department of Leukemia,\u00a0Division of Cancer Medicine,\u00a0The University of Texas MD Anderson Cancer, Houston, TX 77030,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Liu","sequence":"additional","affiliation":[{"name":"GSK plc, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumati","family":"Rao","sequence":"additional","affiliation":[{"name":"GSK plc, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Sajeev","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, MA 02199,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Fillbrunn","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, MA 02199,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Simpson","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, MA 02199,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilong","family":"Li","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, MA 02199,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Yang","sequence":"additional","affiliation":[{"name":"GSK plc, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Le Lorier","sequence":"additional","affiliation":[{"name":"GSK plc, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Gorsh","sequence":"additional","affiliation":[{"name":"GSK plc, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, MA 02199,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"issue":"5","key":"e_1_3_10_3_1","first-page":"299","article-title":"The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs. primary myelofibrosis","volume":"17","author":"Masarova L","year":"2019","unstructured":"Masarova L, Verstovsek S. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs. primary myelofibrosis. Clin Adv Hematol Oncol. 2019;17(5):299\u2013307.","journal-title":"Clin Adv Hematol Oncol."},{"key":"e_1_3_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100691"},{"key":"e_1_3_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23690"},{"key":"e_1_3_10_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1992756"},{"key":"e_1_3_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.118"},{"key":"e_1_3_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.11.001"},{"key":"e_1_3_10_9_1","unstructured":"Leukemia and Lymphoma Society. Myeloproliferative neoplasms (MPN) research funded by the Leukemia and Lymphoma Society. Available from: https:\/\/www.lls.org\/research\/myeloproliferative-neoplasms-mpn-research-funded-lls"},{"key":"e_1_3_10_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000001"},{"key":"e_1_3_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100716"},{"key":"e_1_3_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0447-9"},{"key":"e_1_3_10_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.035519"},{"key":"e_1_3_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0028-x"},{"key":"e_1_3_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006006"},{"key":"e_1_3_10_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01157-4"},{"key":"e_1_3_10_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1016933"},{"key":"e_1_3_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162657"},{"key":"e_1_3_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01238-7"},{"key":"e_1_3_10_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.031831"},{"key":"e_1_3_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13198"},{"key":"e_1_3_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv203"},{"key":"e_1_3_10_23_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00008.2013"},{"key":"e_1_3_10_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1804281"},{"key":"e_1_3_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740092"},{"key":"e_1_3_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002662"},{"key":"e_1_3_10_27_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1048"},{"key":"e_1_3_10_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_3_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"e_1_3_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02036-0"},{"key":"e_1_3_10_31_1","volume-title":"27th Congress of the European Hematology Association 2022","author":"Knoth RL","year":"2022","unstructured":"Knoth RL, Gupta S, Perkowski K, et al. Examining the burden of illness associated with transfusion-dependent beta-thalassemia from the patient's perspective. Poster presented at: 27th Congress of the European Hematology Association 2022. 2022 June 9\u201312, Vienna, Austria and virtually. Poster P1741."},{"key":"e_1_3_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2022.101371"},{"key":"e_1_3_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21574"},{"key":"e_1_3_10_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7066"},{"key":"e_1_3_10_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-020-05461-x"},{"key":"e_1_3_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16640"},{"key":"e_1_3_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103862"},{"key":"e_1_3_10_38_1","volume-title":"ISPOR 18th Annual European Congress","author":"Sly I","year":"2015","unstructured":"Sly I, Yang Y, Lee D. A systemic literature review of the economic burden of myelofibrosis. Poster presented at: ISPOR 18th Annual European Congress. 2015 November 7\u201311; Milan, Italy. Poster PCN107."},{"key":"e_1_3_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01207.x"},{"key":"e_1_3_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3082-y"},{"key":"e_1_3_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.09.001"},{"key":"e_1_3_10_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/20503121211054995"},{"key":"e_1_3_10_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_10_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_3_10_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3194-4"},{"key":"e_1_3_10_46_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151449"},{"key":"e_1_3_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30088-1"},{"key":"e_1_3_10_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006889"},{"key":"e_1_3_10_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab058"},{"key":"e_1_3_10_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0029-4"},{"key":"e_1_3_10_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2435-7"},{"key":"e_1_3_10_52_1","volume-title":"AMCP Annual Meeting","author":"Purser M","year":"2024","unstructured":"Purser M, Liu T, Gorsh B, et al. Estimating the financial impact of introducing momelotinib as a treatment option for adult patients with intermediate-or high-risk myelofibrosis with anemia from a US commercial and Medicare payer perspective. Poster presented at: AMCP Annual Meeting. 2024 April 15\u201318; New Orleans, LA. Poster D16."},{"key":"e_1_3_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.03.599"},{"key":"e_1_3_10_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000975484.93174.12"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2024.2368450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T13:19:30Z","timestamp":1729862370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2024.2368450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":52,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2024,9,22]]}},"alternative-id":["10.1080\/14796694.2024.2368450"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2024.2368450","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}